The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors.
The US Federal Trade Commission has issued a final approval of Fresenius Medical Care’s $2 billion acquisition of medical device company NxStage Medical.
Duane Morris & Selvam has strengthened its IP practice with the addition of John Alison from Winston & Strawn.
Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
The US Food and Drug Administration and US Customs and Border Protection have strengthened their collaboration in a bid to halt the import of counterfeit drugs and protect public health.